177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-11-15
Target enrollment:
Participant gender:
Summary
This is a pilot study to assess the safety and measure image-based absorbed dose of
177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical, in patients with metastatic
castration resistant prostate cancer (mCRPC) who will undergo radioligand therapy (RLT). All
patients underwent 68Ga-PSMA and 18F-FDG PET/CT for selection and were randomly divided into
three groups of 3 people each.The three groups received an approximately 1.11 GBq (30mCi),
1.85 GBq (50 mCi) and 2.59 GBq (70mCi) of 177Lu-PSMA-EB-01 up to 2 cycles, respectively.